David Cipolla PhD

David Cipolla has more than 25 years of experience in the pharmaceutical industry with a focus on the development of formulation and drug delivery technologies to support pharmaceutical product development. David is currently the Vice President of Research at Insmed, Inc, where he is part of a team developing novel, targeted therapies to help serve the critical unmet needs of patients battling serious rare diseases. Prior to joining Insmed in 2018, David was VP of Preclinical Research at Aradigm (1996 to 2018) covering all phases of product development, and before joining Aradigm David worked at Genentech, Inc. (1988 to 1996) developing and characterizing the delivery of protein aerosols to the airways, culminating with the approval of Pulmozyme® rhDNase for the management of cystic fibrosis in 1993.